Precision BioSciences, Inc. (DTIL)

NASDAQ: DTIL · IEX Real-Time Price · USD

9.41

-0.48 (-4.85%)

At close: Jul 2, 2024, 4:00 PM

9.81

+0.40 (4.22%)

After-hours: Jul 2, 2024, 5:51 PM EDT

Precision BioSciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2017
Revenue	48.73	25.1	115.53	24.29	22.24	Upgrade
Revenue Growth (YoY)	94.15%	-78.28%	375.72%	9.20%	104.34%	Upgrade
Gross Profit	48.73	25.1	115.53	24.29	22.24	Upgrade
Selling, General & Admin	39.09	41.28	39.67	36.05	27.03	Upgrade
Research & Development	53.38	46.12	115.24	98.06	82.42	Upgrade
Operating Expenses	92.46	87.41	154.91	134.11	109.44	Upgrade
Operating Income	-43.74	-62.31	-39.38	-109.83	-87.2	Upgrade
Interest Expense / Income	2.23	1.11	0.13	0	0.18	Upgrade
Other Expense / Income	15.35	48.22	-8.91	-0.82	5.49	Upgrade
Pretax Income	-61.32	-111.64	-30.6	-109.01	-92.88	Upgrade
Net Income	-61.32	-111.64	-30.6	-109.01	-92.88	Upgrade
Shares Outstanding (Basic)	4	3	2	2	1	Upgrade
Shares Outstanding (Diluted)	4	3	2	2	1	Upgrade
Shares Change	31.11%	49.77%	12.79%	23.91%	166.18%	Upgrade
EPS (Basic)	-15.96	-38.10	-15.60	-62.70	-66.30	Upgrade
EPS (Diluted)	-15.96	-38.10	-15.60	-62.70	-66.30	Upgrade
Free Cash Flow	-85.96	-49.07	-15.91	-92.42	-95.68	Upgrade
Free Cash Flow Per Share	-22.38	-16.75	-8.13	-53.28	-68.36	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-89.76%	-248.26%	-34.08%	-452.25%	-392.14%	Upgrade
Profit Margin	-125.84%	-444.80%	-26.49%	-448.86%	-417.65%	Upgrade
Free Cash Flow Margin	-176.42%	-195.52%	-13.77%	-380.55%	-430.26%	Upgrade
EBITDA	-50.83	-101.52	-20.27	-99.19	-87.38	Upgrade
EBITDA Margin	-104.32%	-404.50%	-17.55%	-408.45%	-392.92%	Upgrade
Depreciation & Amortization	8.26	9	10.2	9.81	5.32	Upgrade
EBIT	-59.09	-110.53	-30.47	-109.01	-92.7	Upgrade
EBIT Margin	-121.27%	-440.38%	-26.37%	-448.86%	-416.83%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).